An ALLG phase 3 randomised trial of Selinexor and Lenalidomide - versus Lenalidomide maintenance post Autologous Stem Cell Transplant for patients with Newly Diagnosed Multiple Myeloma (MM23)

Full description

This dataset contains individual participant data (IPD) from the MM23 study, a phase III randomised trial evaluating selinexor and lenalidomide versus lenalidomide maintenance following autologous stem cell transplant in patients with newly diagnosed multiple myeloma. This dataset includes data for ALLG MM23 trial participants TOTAL 195 Patients recruited in the study (135 male, 60 female, with newly-diagnosed Multiple Myeloma, taking part in the PHASE 3 SeaLAND study. Data for, 2 ARMS are available (Selinexor + Lenalidomide AND Lenalidomide only) Participants were recruited at sites Australia wide, and includes data from treatment until disease progression, and minimum 1 year period in follow up. The study commenced in January 2021 and conducted the last patient last visit in September 2025. Dataset includes timepoints pre- and post-ASCT correlative samples, QOL and PROs. Trial deemed futile in June 2024. Cancer Australia demographic data: • Year of birth • Postcode of home address • Aboriginal or Torres Strait Islander status (or Ethnicity) • Culturally and Linguistically Diverse (CALD) status:

Notes

HeSANDA 1.0.0